Resverlogix Corp RVXCF
Trading Information
- Previous Close Price
- $0.06
- Day Range
- $0.06–0.07
- 52-Week Range
- $0.05–0.10
- Bid/Ask
- $0.05 / $5.00
- Shares Outstanding
- 344.29M
- Market Cap
- $19.66M
- Volume/Avg
- 80,400 / 16,283
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease, including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 17
- Website
- https://www.resverlogix.com
Valuation
|
Metric
|
RVXCF
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
RVXCF
|
|---|---|
Quick Ratio | 0.03 |
Current Ratio | 0.04 |
Interest Coverage | −1.21 |
Quick Ratio
RVXCF
Profitability
|
Metric
|
RVXCF
|
|---|---|
Return on Assets (Normalized) | −121.84% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
RVXCF
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|$kvhqS | LOCK|#Kc$w | $128B | |||
| Moderna Inc
MRNA
| LOCK|bqs>!sr | LOCK|?@f | $76B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|!<kPf<^ | LOCK|rP<@B | $76B | |||
| argenx SE ADR
ARGX
| LOCK|K$?MQ#v | LOCK|Q?v | $57B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|^$jC>Q | LOCK|VWS | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|?!&!fDC | LOCK|pfKl | $29B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|%tn%bxV | LOCK|&GPT | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|S&K>%$S | LOCK|wP | $24B | |||
| Incyte Corp
INCY
| LOCK|c@?<?> | LOCK|$j | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|H#f^#^# | LOCK|?%w | $15B |
United States